Shared from twixb · endpts.com
Natalie Holles quickly transitioned to a new opportunity following the shutdown of her previous company, Third Harmonic, while Mark Alles has stepped down from his role at ADC Biotech.
The content does not provide any specific insights or actionable takeaways related to healthtech, biotech, or digital health that would be valuable to the reader.
Powered by twixb
twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.
Recent stories curated alongside this one.
Novo Nordisk has secured a partnership for its early-stage Parkinson's cell therapy, while also announcing label expansions for two drugs aimed at rare diseases. Additionally, Genmab has discontinued a Phase 1 cancer trial.
Inhibrx, a biotech company based in San Diego, reports that its experimental drug INBRX-106, when combined with Merck's Keytruda, was more effective in shrinking tumors in patients with metastatic head cancer than Keytruda alone.
The FDA is facing potential leadership changes with questions about Commissioner Marty Makary's future, while there are developments in a revived gene therapy for a rare disease and disappointing adoption rates for Alzheimer's drugs.
Inhibrx Biosciences' OX40 agonist combined with Keytruda significantly increased response rates in a midphase clinical trial, prompting the biotech to move forward with the program, which has garnered interest from Merck & Co.
Enterprise Therapeutics' cystic fibrosis drug candidate has successfully met its primary endpoint in a phase 2 trial, advancing the company's efforts in a field previously explored by other firms like Vertex.
